本站原创
[摘要] 目的 观察葛根素联合生脉注射液治疗小儿病毒性心肌炎的临床疗效。 方法 将66例小儿病毒性心肌炎患者随机分为3组。3组均给予常规治疗，治疗组Ⅰ在常规治疗的基础上加用生脉注射液，治疗组Ⅱ在治疗组Ⅰ的基础上加用葛根素注射液。观察治疗前后症状、体征、心电图、心肌酶谱等指标的变化。 结果 治疗组Ⅰ在各项指标上明显优于对照组（P < 0.05）。治疗组Ⅱ与治疗组Ⅰ相比，各项指标的改善情况更为明显（P < 0.05）。 结论 生脉注射液治疗小儿病毒性心肌炎疗效显著。葛根素联合生脉注射液治疗疗效更佳，值得临床推广。
[关键词] 葛根素；生脉注射液；病毒性心肌炎；疗效
[] A[文章编号] 1674-4721（2012）07（c）-0146-02
Effect analysis of puerarin and shengmai injection on children with viral myocarditis
PENG Yongjun1 YI Qijian2▲
1.Department of Pediatrics, People′s Hospital of Youyang Country in Chongqing City, Chongqing 409800, China; 2.Children′s Hospital of Chongqing Medical University, Chongqing 400014, China
[Abstract] Objective To observe the clinical effect of puerarin and shengmai injection on children with viral myocarditis(VMC). Methods Sixty six cases were randomly divided into three groups: control group (common treatment), teatment group Ⅰ (shengmai injection treatment) and treatment group Ⅱ (pueratin and shengmai injection treatment). Clinical symptoms, objective signs，electrocardiogram and cardiac enzyme were determined before and after treatment. Results Compared with those in control group, teatment group Ⅰis better (P < 0.05), and treatment group Ⅱis the best in the three (P < 0.05). Conclusion It is safe and effective to treat the children with VMC with puerarin and shengmai injection combined with ordinary medicine.
[Key words] Puerarin; Shengmai injection; Viral myocarditis; Effect
小儿病毒性心肌炎（viral myocarditis，VMC）是由病毒感染引起的，以局限性或弥漫性心肌炎性病变为主要特征的儿科临床上常见的心血管系统疾病之一。近年来，其发病率逐年上升，严重危害了少年儿童的身体健康。但至今一直缺乏特效的治疗措施。笔者采用葛根素联合生脉注射液治疗小儿VCM取得满意的临床疗效，现报道如下：
[关键词] 葛根素；生脉注射液；病毒性心肌炎；疗效
[] A[文章编号] 1674-4721（2012）07（c）-0146-02
Effect analysis of puerarin and shengmai injection on children with viral myocarditis
PENG Yongjun1 YI Qijian2▲
1.Department of Pediatrics, People′s Hospital of Youyang Country in Chongqing City, Chongqing 409800, China; 2.Children′s Hospital of Chongqing Medical University, Chongqing 400014, China
[Abstract] Objective To observe the clinical effect of puerarin and shengmai injection on children with viral myocarditis(VMC). Methods Sixty six cases were randomly divided into three groups: control group (common treatment), teatment group Ⅰ (shengmai injection treatment) and treatment group Ⅱ (pueratin and shengmai injection treatment). Clinical symptoms, objective signs，electrocardiogram and cardiac enzyme were determined before and after treatment. Results Compared with those in control group, teatment group Ⅰis better (P < 0.05), and treatment group Ⅱis the best in the three (P < 0.05). Conclusion It is safe and effective to treat the children with VMC with puerarin and shengmai injection combined with ordinary medicine.
[Key words] Puerarin; Shengmai injection; Viral myocarditis; Effect
小儿病毒性心肌炎（viral myocarditis，VMC）是由病毒感染引起的，以局限性或弥漫性心肌炎性病变为主要特征的儿科临床上常见的心血管系统疾病之一。近年来，其发病率逐年上升，严重危害了少年儿童的身体健康。但至今一直缺乏特效的治疗措施。笔者采用葛根素联合生脉注射液治疗小儿VCM取得满意的临床疗效，现报道如下：
1 资料与方法
1.1 一般资料
选择2009年8月～2011年8月在本院住院的病毒性心肌炎患儿66例，均符合全国小儿心血管专业学术会议制订的《小儿病毒性心肌炎诊断标准》。其中，男36例，女30例，随机分为3组。对照组24例，其中，男1源于：免费论文查重www.udooo.com
3例，女11例；年龄1～14岁，平均6.2岁。治疗组Ⅰ22例，其中，男11例，女11例，年龄2～16岁，平均5.9 岁。治疗组Ⅱ20例，男12例，女8例；年龄1～12岁，平均6.1岁。3组性别、年龄、病程、疾病程度等比较，差异均无统计学意义（P > 0.05），具有可比性。1.2 治疗方法
对照组和治疗组患儿常规治疗方法相同，均卧床休息，给予利巴韦林10～15 mg/（kg·d），维生素C 100～200 mg／（kg·d），ATP 20～40 mg/d、辅酶A 50～100 U/d，1 次/d，14 d为1个疗程。治疗组Ⅰ加用生脉注射液（四川宜宾五粮液集团宜宾制药有限公司），<7岁者10 mL，>7岁者20 mL，稀释后静脉滴注，1次/d，14 d为1个疗程。治疗组Ⅱ在治疗组Ⅰ的基础上加用葛根素注射液（江苏扬子江药业有限公司生产），<7岁者200 mg/d，>7岁者400 mg/d，稀释后静脉滴注，1次/d，连用14 d，为1个疗程。1.3 观察指标
对照组和治疗组患儿在治疗前后观察以下指标：（1）症状、体征变化；（2）心电图、X线胸片及心脏彩超检查；（3）血清心肌酶谱检测[测定谷草转氨酶（AST）、肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）、乳酸脱氢酶（LDH）、α羟丁酸脱氢酶（α-HBDH）]。1.4 疗效判定标准
显效：临床自觉症状消失，心电图异常消失、心肌酶谱恢复到正常范围内，心脏扩大消失；有效：临床自觉症状好转或减轻，心电图异常减轻或偶有异常、心肌酶谱有明显改善；无效：临床自觉症状及心电图、心肌酶谱均无明显好转。源于：初中英语论文www.udooo.com